A case-control study of oral contraceptive use and incident breast cancer

American Journal of Epidemiology

Volumn 169, Issue 4, 2009, Pages 473-479

  Rosenberg, Lynn ^a   Zhang, Yuqing ^b   Coogan, Patricia F ^a   Strom, Brian L ^c,d   Palmer, Julie R ^a  

^a BOSTON UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Center for Education and Research on Therapeutics   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Breast neoplasms; Case control studies; Contraceptives, oral

Indexed keywords

ESTROGEN RECEPTOR; ORAL CONTRACEPTIVE AGENT; PROGESTERONE RECEPTOR;

CANCER; CONTRACEPTIVE USE; DISEASE INCIDENCE; ETHNICITY; HORMONE; QUESTIONNAIRE SURVEY; RISK FACTOR; TUMOR; WOMENS HEALTH;

ADULT; AFRICAN AMERICAN; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CASE CONTROL STUDY; CONTROLLED STUDY; DRUG USE; ETHNIC DIFFERENCE; EUROPEAN AMERICAN; FEMALE; HUMAN; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; RISK ASSESSMENT; TREATMENT DURATION;

ADULT; AFRICAN AMERICANS; AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL; ETHNIC GROUPS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; INCIDENCE; INTERVIEWS AS TOPIC; LOGISTIC MODELS; MIDDLE AGED; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RISK FACTORS; TIME FACTORS; UNITED STATES;

NORTH AMERICA; UNITED STATES;

EID: 60149089809     PISSN: 00029262     EISSN: 14766256     Source Type: Journal    
DOI: 10.1093/aje/kwn360     Document Type: Article

References (48)

1. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Lancet. 1996;347(9017):1713-1727.
2. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and hormonal contraceptives: further results. Contraception. 1996;54(3 suppl):1S-106S.
3. Piper JM, Kennedy DL. Oral contraceptives in the United States: trends in content and potency. Int J Epidemiol. 1987;16(2):215-221.
4. Newton JR. Classification and comparison of oral contraceptives containing new generation progestogens. Hum Reprod Update. 1995;1(3):231-263.
5. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives. N Engl J Med. 2003;349(15):1443-1450.
6. Gerstman BB, Gross TP, Kennedy DL, et al. Trends in the content and use of oral contraceptives in the United States, 1964-88. Am J Public Health. 1991;81(1):90-96.
7. Kumle M, Weiderpass E, Braaten T, et al. Use of oral contraceptives and breast cancer risk: The Norwegian-Swedish Women's Lifestyle and Health Cohort Study. Cancer Epidemiol Biomarkers Prev. 2002;11(11):1375-1381.
8. Hankinson SE, Colditz GA, Manson JE, et al. A prospective study of oral contraceptive use and risk of breast cancer (Nurses' Health Study, United States). Cancer Causes Control. 1997;8(1):65-72.
9. Moorman PG, Millikan RC, Newman B. Oral contraceptives and breast cancer among African-American women and white women. J Natl Med Assoc. 2001;93(9):329-334.
10. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med. 2002;346(26):2025-2032.
11. Shantakumar S, Terry MB, PaykinA, et al. Age and menopausal effects of hormonal birth control and hormone replacement therapy in relation to breast cancer risk. Am J Epidemiol. 2007;165(10):1187-1198.
12. Van Hoften C, Burger H, Peeters PH, et al. Long-term oral contraceptive use increases breast cancer risk in women over 55 years of age: the DOM cohort. Int J Cancer. 2000;87(4):591-594.
13. Ma H, Bernstein L, Ross RK, et al. Hormone-related risk factors for breast cancer in women under age 50 years by estrogen and progesterone receptor status: results from a case-control and a case-case comparison [electronic article]. Breast Cancer Res. 2006;8(4):R39.
14. Palmer JR, Rosenberg L, Rao RS, et al. Oral contraceptive use and breast cancer risk among African-American women. Cancer Causes Control. 1995;6(4):321-331.
15. Brinton LA, Gammon MD, Malone KE, et al. Modification of oral contraceptive relationships on breast cancer risk by selected factors among younger women. Contraception. 1997;55(4):197-203.
16. Mayberry RM, Stoddard-Wright C. Breast cancer risk factors among black women and white women: similarities and differences. Am J Epidemiol. 1992;136(12):1445-1456.
17. Hall IJ, Moorman PG, Millikan RC, et al. Comparative analysis of breast cancer risk factors among African-American women and white women. Am J Epidemiol. 2005;161(1):40-51.
18. Mayberry RM. Age-specific patterns of association between breast cancer and risk factors in black women, ages 20 to 39 and 40 to 54. Ann Epidemiol. 1994;4(3):205-213.
19. Althuis MD, Brogan DD, Coates RJ, et al. Breast cancers among very young premenopausal women (United States). Cancer Causes Control. 2003;14(2):151-160.
20. Cooper JA, Rohan TE, Cant EL, et al. Risk factors for breast cancer by oestrogen receptor status: a population-based case-control study. Br J Cancer. 1989;59(1):119-125.
21. Cotterchio M, Kreiger N, Theis B, et al. Hormonal factors and the risk of breast cancer according to estrogen- and progesterone-receptor subgroup. Cancer Epidemiol Biomarkers Prev. 2003;12(10):1053-1060.
22. Huang WY, Newman B, Millikan RC, et al. Hormone-related factors and risk of breast cancer in relation to estrogen receptor and progesterone receptor status. Am J Epidemiol. 2000;151(7):703-714.
23. McCredie MR, Dite GS, Southey MC, et al. Risk factors for breast cancer in young women by oestrogen receptor and progesterone receptor status. Br J Cancer. 2003;89(9):1661-1663.
24. McTiernan A, Thomas DB, Johnson LK, et al. Risk factors for estrogen receptor-rich and estrogen receptor-poor breast cancers. J Natl Cancer Inst. 1986;77(4):849-854.
25. Stanford JL, Szklo M, Boring CC, et al. A case-control study of breast cancer stratified by estrogen receptor status. Am J Epidemiol. 1987;125(2):184-194.
26. Althuis MD, Fergenbaum JH, Garcia-Closas M, et al. Etiology of hormone receptor-defined breast cancer: a systematic review of the literature. Cancer Epidemiol Biomarkers Prev. 2004;13(10):1558-1568.
27. Rosenberg L, Palmer JR, Rao RS, et al. Case-control study of oral contraceptive use and risk of breast cancer. Am J Epidemiol. 1996;143(1):25-37.
28. Rothman K, Greenland S, Lash T. Modern Epidemiology. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2008:118-119.
29. Rosenberg L, Palmer JR, Rao RS, et al. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med. 2001;161(8):1065-1070.
30. Maia HJ, Casoy J. Non-contraceptive health benefits of oral contraceptives. Eur J Contracept Reprod Health Care. 2008;13(1):17-24.
31. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and survival. Breast Cancer Res Treat. 2002;73(1):45-59.
32. West S, Strom B, Poole C. Validity of pharmacoepidemiologic drug and diagnosis data. In: Strom B, ed. Pharmacoepidemiology. 4th ed. Chichester, United Kingdom: John Wiley & Sons Ltd; 2005:719-720.
33. Kaufman DW, Shapiro S, Slone D, et al. Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med. 1980;303(18):1045- 1047.
34. Rosenberg L, Shapiro S, Slone D, et al. Epithelial ovarian cancer and combination oral contraceptives. JAMA. 1982;247(23):3210-3212.
35. Rosenberg L, Palmer JR, Zauber AG, et al. A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol. 1994;139(7):654-661.
36. Palmer JR, Rosenberg L, Kaufman DW, et al. Oral contraceptive use and liver cancer. Am J Epidemiol. 1989;130(5):878-882.
37. Tworoger SS, Fairfield KM, Colditz GA, et al. Association of oral contraceptive use, other contraceptive methods, and infertility with ovarian cancer risk. Am J Epidemiol. 2007;166(8):894-901.
38. Burkman R, Schlesselman JJ, Zieman M. Safety concerns and health benefits associated with oral contraception. Am J Obstet Gynecol. 2004;190(4 suppl):S5-S22.
39. Helmrich SP, Shapiro S, Rosenberg L, et al. Risk factors for breast cancer. Am J Epidemiol. 1983;117(1):35-45.
40. Schatzkin A, Palmer JR, Rosenberg L, et al. Risk factors for breast cancer in black women. J Natl Cancer Inst. 1987;78(2):213-217.
41. Palmer JR, Rosenberg L, Harlap S, et al. Adult height and risk of breast cancer among US black women. Am J Epidemiol. 1995;141(9):845-849.
42. Zhang Y, Rosenberg L, Colton T, et al. Adult height and risk of breast cancer among white women in a case-control study. Am J Epidemiol. 1996;143(11):1123-1128.
43. Palmer JR, Rosenberg L, Rao RS, et al. Induced and spontaneous abortion in relation to risk of breast cancer (United States). Cancer Causes Control. 1997;8(6):841-849.
44. Kelsey JL, Gammon MD, John EM. Reproductive factors and breast cancer. Epidemiol Rev. 1993;15(1):36-47.
45. Swanson CA, Jones DY, Schatzkin A, et al. Breast cancer risk assessed by anthropometry in the NHANES I Epidemiological Follow-up Study. Cancer Res. 1988;48(18):5363-5367.
46. Tretli S. Height and weight in relation to breast cancer morbidity and mortality. A prospective study of 570,000 women in Norway. Int J Cancer. 1989;44(1):23-30.
47. Brinton LA, Swanson CA. Height and weight at various ages and risk of breast cancer. Ann Epidemiol. 1992;2(5):597-609.
48. Melbye M, Wohlfahrt J, Olsen JH, et al. Induced abortion and the risk of breast cancer. N Engl J Med. 1997;336(2):81-85.